Evidence map›Paper›PMID 25374542›Full record

ArticleFrontiers in pharmacology2014

Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models.

Sergey Ermakov, Peter Forster, Jyotsna Pagidala, Marko Miladinov, Albert Wang, Rebecca Baillie, Derek Bartlett, Mike Reed, Tarek A Leil

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. gPKPDSim: a SimBiologyJournal of pharmacokinetics and pharmacodynamics · 2018
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sergey ErmakovExploratory Clinical and Translational Research, Bristol-Myers Squibb Princeton, NJ, USA.
Peter ForsterForster Solutions, LLC Wilmington, DE, USA.
Jyotsna PagidalaResearch IT and Automation, Bristol-Myers Squibb Princeton, NJ, USA.
Marko MiladinovResearch IT and Automation, Bristol-Myers Squibb Princeton, NJ, USA.
Albert WangResearch IT and Automation, Bristol-Myers Squibb Princeton, NJ, USA.
Rebecca BaillieRosa & Co. LLC San Carlos, CA, USA.
Derek BartlettRosa & Co. LLC San Carlos, CA, USA.
Mike ReedRosa & Co. LLC San Carlos, CA, USA.
Tarek A LeilExploratory Clinical and Translational Research, Bristol-Myers Squibb Princeton, NJ, USA.
Bristol-Myers Squibb (United States) · USRosa (United States) · USWilmington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple software programs are available for designing and running large scale system-level pharmacology models used in the drug development process. Depending on the problem, scientists may be forced to use several modeling tools that could increase model development time, IT costs and so on. Therefore, it is desirable to have a single platform that allows setting up and running large-scale simulations for the models that have been developed with different modeling tools. We developed a workflow and a software platform in which a model file is compiled into a self-contained executable that is no longer dependent on the software that was used to create the model. At the same time the full model specifics is preserved by presenting all model parameters as input parameters for the executable. This platform was implemented as a model agnostic, therapeutic area agnostic and web-based application with a database back-end that can be used to configure, manage and execute large-scale simulations for multiple models by multiple users. The user interface is designed to be easily configurable to reflect the specifics of the model and the user's particular needs and the back-end database has been implemented to store and manage all aspects of the systems, such as Models, Virtual Patients, User Interface Settings, and Results. The platform can be adapted and deployed on an existing cluster or cloud computing environment. Its use was demonstrated with a metabolic disease systems pharmacology model that simulates the effects of two antidiabetic drugs, metformin and fasiglifam, in type 2 diabetes mellitus patients.

Indexed as

metabolic diseases modelmodel development softwarequantitative systems pharmacologysimulation experimentsystem-level mechanistic modelsvirtual patient

Identifiers

PMID25374542
PMCPMC4205926
OpenAlexW2057379834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.